

## **CURRENT REPORT 6/2021**

**March 11, 2021**

### **Ryvu Therapeutics to present recent data from multiple oncology programs at AACR 2021 Virtual Annual Meeting**

The Management Board of Ryvu Therapeutics S.A. ("Company") hereby announces that during the upcoming American Association of Cancer Research (AACR) Virtual Annual Meeting 2021, April 10-15 and May 17-21 Company will present data from multiple oncology programs: RVU120 (SEL120), a CDK8/CDK19 inhibitor program, as well as data from small-molecule STING agonists and HPK1 inhibitors.

Details of the e-poster presentations are as follows:

- Title: SEL120, a CDK8/CDK19 inhibitor, possesses strong multilineage differentiation potential in AML  
Permanent Abstract Number: 1018
- Title: New generation of STING agonists - development and characterization of a novel series of systemic immunomodulators with improved potency  
Permanent Abstract Number: 1280
- Title: Development and characterization of small molecule HPK1 inhibitors  
Permanent Abstract Number: 1281

The e-poster website will be launched on Saturday, April 10. All e-posters will be made available for browsing on this date through to June 21, 2021.

Additional information is available on the AACR conference website <http://www.aacr.org>.

The information was considered significant because the research results of projects in the Company's pipeline are of key importance for its valuation, and the AACR conference is considered one of the most important scientific events, gathering researchers, as well as potential clients and business partners - biotechnology and pharmaceutical companies and industry investors.

#### **Legal basis: art. 17 ust. 1 MAR**

#### **Representatives of the Company:**

- Paweł Przewięźlikowski – President of the Management Board
- Krzysztof Brzózka – Vice President of the Management Board